Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Pfizer Inc
Pfizer Inc And Renovis Inc
Pfizer Inc Products Inc
Pfizer Inc Pfizer Products Inc

Pfizer Inc patents (2015 archive)


Recent patent applications related to Pfizer Inc. Pfizer Inc is listed as an Agent/Assignee. Note: Pfizer Inc may have other listings under different names/spellings. We're not affiliated with Pfizer Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pfizer Inc-related inventors


12/31/15 / #the present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of formula i,

Pfizer Inc.

. . ... Pfizer Inc

12/31/15 / #the invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

12/24/15 / #the present invention provides novel 4,5-disubstituted-7h-pyrrolo[2,3-d]pyrimidine derivatives of formula i, and the pharmaceutically acceptable salts thereof

Pfizer Inc.

. . ... Pfizer Inc

12/17/15 / #this invention relates to compounds of general formula (i)

Pfizer Inc.

. . ... Pfizer Inc

12/10/15 / #the present invention provides a compound of formula i

Pfizer Inc.

. . ... Pfizer Inc

12/10/15 / #20150353579

Triazine derivatives

The present invention is directed to a new class of triazine derivatives as described by formula i below in which a, x, r1, r2, r3, and r4 are as defined herein and to the use of the compounds as pde10 inhibitors.. . ... Pfizer Inc

12/03/15 / #the present invention provides, in part, compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

11/26/15 / #the invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

11/26/15 / #20150337054

Anti-tofacitinib antibodies and uses thereof for drug monitoring

The invention provides selective tofacitinib antibodies, immunogenic tofacitinib conjugates that are useful as immunogenic molecules for the generation of antibodies specific for tofacitinib, along with methods for measuring the concentration of tofacitinib in a sample, processes for making the antibodies, and assays and kits for using the antibodies.. . ... Pfizer Inc

11/26/15 / #20150337032

Antagonist antibodies against gdf-8 and uses therefor

The disclosure provides improved neutralizing anti-gdf-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-gdf-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.. ... Pfizer Inc

11/19/15 / #a compound having the structure:

Pfizer Inc.

. . ... Pfizer Inc

11/19/15 / #20150329555

Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr

Compounds of formula (a) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (asgpr) targeting agents.. . ... Pfizer Inc

11/19/15 / #20150329520

Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction

The present invention relates in part to chemical compounds, and methods for producing these compounds. The compounds may also be incorporated into compositions to enhance quit rates or reduce relapse in smoking cessation and further in treating nicotine-related dependence.. ... Pfizer Inc

11/19/15 / #20150328328

Glycoconjugation process

The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.. . ... Pfizer Inc

11/12/15 / #the present invention relates to compounds of formula i

Pfizer Inc

. . ... Pfizer Inc

11/12/15 / #the present invention is directed to compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

11/12/15 / #20150322135

Engineered monomeric antibody fragments

The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric fc-containing polypeptides) wherein the monomeric fc comprises one or more engineered n-linked glycosylation sites in the ch3-ch3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.. ... Pfizer Inc

11/05/15 / #20150315293

Anti-ptk7 antibody-drug conjugates

The present invention provides anti-ptk7 antibody-drug conjugates and methods for preparing and using the same.. . ... Pfizer Inc

10/29/15 / #the present invention provides, in part, compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

10/29/15 / #20150307551

Cytotoxic peptides and antibody drug conjugates thereof

The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.. . ... Pfizer Inc

10/29/15 / #20150306234

Muteins of clotting factor vlll

The present disclosure provides muteins of fviii to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.. . ... Pfizer Inc

10/01/15 / #compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula i

Pfizer Inc.

. . ... Pfizer Inc

10/01/15 / #20150274735

Use of a tetrasubstituted pyrazolo[4, 3-d]pyrimidine compound for treating diabetic nephropathy

The present invention relates to methods of delaying progression to end stage renal disease (esrd) in patients comprising administration of 1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methyl-pyridin-2-yl)amino)-n-(methylsulfonyl)-1h-pyrazolo[4,3-d]pyrimidine-3-carboxamide. The present invention also includes administration of pharmaceutical compositions for delaying progression to esrd. ... Pfizer Inc

10/01/15 / #20150274659

Process for annealing amorphous atorvastatin

Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.. ... Pfizer Inc

09/24/15 / #the present invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

09/24/15 / #20150266974

Antibodies with ph dependent antigen binding

The present invention relates to antibodies with ph dependent binding to its antigen such that the affinity for antigen binding at physiological ph (i.e., ph 7.4) is greater than at endosomal ph (i.e., ph 6.0 or 5.5). In other words, the kd or koff ratio at ph 5.5/ph 7.4 or at ph 6.0/ph 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. ... Pfizer Inc

09/24/15 / #20150266962

Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates

Disclosed herein are anti-il-13-rα2 antibodies and antibody drug conjugates and methods for preparing and using the same.. . ... Pfizer Inc

09/17/15 / #the present invention relates to new sulfonamide urat-1 inhibitor compounds of formula (i) or a pharmaceutically acceptable salt thereof:

Pfizer Limited

. . ... Pfizer Inc

09/17/15 / #the present invention relates to imidazopyridazine derivatives. more particularly, it relates to 4-(biphenyl-3-yl)-7h-imidazo[4,5-c]pyridazine derivatives of formula (i):

Pfizer Limited

. . ... Pfizer Inc

09/17/15 / #20150259323

Diacylglycerol acyltransferase 2 inhibitors

Compounds of formula i that inhibit the activity of the diacylglycerol acyltransferase 2 (dgat2) and their uses in the treatment of diseases linked thereto in animals are described herein.. . ... Pfizer Inc

09/10/15 / #the present invention relates to compounds of formula (ia) and (ib)

Pfizer Limited

. . ... Pfizer Inc

09/10/15 / #20150251999

Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid

Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and alzheimer's disease.. . ... Pfizer Inc

09/03/15 / #the present invention relates to compounds of formula (i)

Pfizer Limited

. . ... Pfizer Inc

09/03/15 / #20150246106

Prostate-associated antigens and vaccine-based immunotherapy regimens

The present disclosure provides (a) isolated immunogenic paa polypeptides; (b) isolated nucleic acid molecules encoding immunogenic paa polypeptides; (c) vaccine compositions comprising an immunogenic paa polypeptide or an isolated nucleic acid molecule encoding an immunogenic paa polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.. . ... Pfizer Inc

09/03/15 / #20150246048

Pyrrolo[2,3-d]pyrimidine derivatives

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as janus kinase (jak) inhibitors, and pharmaceutical compositions containing them.. . ... Pfizer Inc

08/27/15 / #20150239908

Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula i, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.. ... Pfizer Inc

08/27/15 / #20150239867

Process for the preparation of voriconazole and analogues thereof

The present invention provides a process for preparing a compound of formula: (formula xi and xii) (xi) (xii) wherein x, y, z, a, b and e are as defined herein, by reacting a compound of formula: (formula xiii) (xiii) with a compound of formula: (formula xiv and xv) (xiv) (xv) respectively, in the presence of a transition metal catalyst, a ligand suitable for use with 15 the catalyst and a reducing agent. The invention also provides novel intermediates.. ... Pfizer Inc

08/27/15 / #20150239842

Benzamide and heterobenzamide compounds

This invention relates to compounds of general formula (i), in which r1, r2, r6, u, v, w, x, y and z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.. . ... Pfizer Inc

08/27/15 / #20150238504

Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(adp-ribose) polymerase activity including the disease condition such as cancer.. ... Pfizer Inc

08/20/15 / #the present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula i:

Pfizer Inc.

. . ... Pfizer Inc

08/20/15 / #the present invention provides compounds of formula i, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure

Pfizer Inc.

. . ... Pfizer Inc

08/13/15 / #the present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of formula i,

Pfizer Inc.

. . ... Pfizer Inc

08/13/15 / #20150225408

Pyrrolo[2,3-d]pyrimidine derivatives

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as janus kinase (jak) inhibitors, and pharmaceutical compositions containing them.. . ... Pfizer Inc

08/13/15 / #20150224053

Apixaban solution formulations

Apixaban liquid formulation is provided. Also provided is a method of administering an apixaban liquid formulation.. ... Pfizer Inc

08/06/15 / #the present invention relates to compounds of formula (i)

Pfizer Limited

. . ... Pfizer Inc

08/06/15 / #20150216996

Glycoconjugation processes and compositions

The invention provides etec linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (etec) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.. . ... Pfizer Inc

07/30/15 / #20150209445

Bifunctional cytotoxic agents

Cytotoxic dimers comprising cbi-based and/or cpi-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.. . ... Pfizer Inc

07/23/15 / #the present invention relates to compounds of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

07/23/15 / #20150203574

Antibodies to il-6 and their uses

Antibodies and antigen-binding portions thereof that bind to human il-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.. ... Pfizer Inc

07/23/15 / #20150202309

Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

The present invention relates to new immunogenic compositions comprising conjugated streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a s. ... Pfizer Inc

07/16/15 / #the present invention provides, in part, compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

07/09/15 / #20150190346

Compositions and methods for treatment of abnormal cell growth

This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.. . ... Pfizer Inc

07/02/15 / #20150182604

Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Compositions are provided comprising recombinant variants of the human clotting factor xa. Such compositions include a wide variety of isoforms and post-translational modifications of fxa and are useful for treating subjects in need of hemostasis.. ... Pfizer Inc

07/02/15 / #20150182513

N-link hydroxamic acid derivatives useful as antibacterial agents

The present invention is directed to a new class of hydroxamic acid derivatives, their use as lpxc inhibitors, and more specifically their use to treat bacterial infections.. . ... Pfizer Inc

06/25/15 / #this invention relates to compounds of general formula (i)

Pfizer Inc.

. . ... Pfizer Inc

06/25/15 / #the present invention provides, in part, compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc

06/25/15 / #20150177252

Circulating tumor cell assay

Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (igf-1r) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. ... Pfizer Inc

06/25/15 / #20150175603

Tricyclic compounds as kat ii inhibitors

Compounds of formula (i), wherein r1, r2, x1, y1, z1, and z2 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.. . ... Pfizer Inc

06/25/15 / #20150174182

Pre moistened wipes for use in treating anal rectal irritations and disorders

Many people who suffer from anal rectal discomfort and disorders need fibrous sheet materials which are pre-moistened with a solution for improved cleansing without excessive skin irritation. The invention particularly concerns wet wipes, such as anal-rectal wipes, which comprises a solution comprising hamamelis water or witch hazel, to effectively treat anal-rectal disorders.. ... Pfizer Inc

06/18/15 / #20150167020

Site-specific integration

The present invention relates to stable and high-producing site-specific integration (ssi) host cells, e.g. Chinese hamster ovary (cho)-derived host cells, methods to produce and to use them.. ... Pfizer Inc

06/11/15 / #the present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (iii):

Pfizer Vaccines Llc

. . ... Pfizer Inc

06/11/15 / #20150159134

Method for producing retinal pigment epithelial cells

The invention relates to a method for producing retinal pigment epithelial cells.. . ... Pfizer Inc

06/11/15 / #20150158864

Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting janus kinase (jak). ... Pfizer Inc

06/04/15 / #the invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

05/28/15 / #20150148326

Monobactams

The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.. . ... Pfizer Inc

05/21/15 / #the present invention relates to compounds of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

05/07/15 / #20150125472

Anti-efna4 antibody-drug conjugates

The present invention provides for anti-efna4 antibody-drug conjugates and methods for preparing and using the same.. . ... Pfizer Inc

05/07/15 / #20150125465

Vectors for expression of prostate-associated antigens

The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic paa polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.. . ... Pfizer Inc

04/30/15 / #20150119381

Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient.. ... Pfizer Inc

04/30/15 / #20150118256

Ige ch3 peptide vaccine

The present invention relates to the provision of novel immunogens comprising an antigenic ige peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of ige-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.. ... Pfizer Inc

04/23/15 / #the invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

04/16/15 / #the present invention relates to imidazopyridazine derivatives. more particularly, it relates to 4-(biphenyl-3-yl)-7h-imidazo[4,5-c]pyridazine derivatives of formula (i):

Pfizer Limited

. . ... Pfizer Inc

04/16/15 / #20150104409

Human monoclonal antibodies to ctla-4

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic t-lymphocyte antigen 4 (ctla-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (cdrs), specifically from within fr1 and/or cdr1 through cdr3 and/or within fr4, are provided. ... Pfizer Inc

04/09/15 / #the present invention relates to compounds and pharmaceutically acceptable salts of formulas a and b:

Pfizer Inc.

. . ... Pfizer Inc

04/09/15 / #the present invention provides a compound of formula i

Pfizer Inc.

. . ... Pfizer Inc

04/09/15 / #20150099782

Antagonists of prostaglandin ep3 receptor

Provided herein are antagonists of prostaglandin ep3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.. . ... Pfizer Inc

04/09/15 / #20150098957

Pcsk9 vaccine

The present invention relates to the provision of novel immunogens comprising an antigenic pcsk9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of pcsk9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.. ... Pfizer Inc

04/02/15 / #the present invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

03/26/15 / #compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula i,

Pfizer Inc.

. . ... Pfizer Inc

03/26/15 / #20150087585

Diacylglycerol acyltransferase 2 inhibitors

Derivatives of purine, 3h-imidazo[4,5-b]pyrimidine and 1h-imidazo[4,5-d]pyrazine of formula i that inhibit the activity of the diacylglycerol acyltransferase 2 (dgat2) and their uses in the treatment of diseases linked thereto in animals are described herein.. . ... Pfizer Inc

03/19/15 / #20150080401

Triazine derivatives

The present invention is directed to a new class of triazine derivatives as described by formula i below in which a, x, r1, r2, r3, and r4 are as defined herein and to the use of the compounds as pde10 inhibitors.. . ... Pfizer Inc

03/12/15 / #compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of formula i

Pfizer Inc.

. . ... Pfizer Inc

03/12/15 / #20150071959

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride. ... Pfizer Inc

03/05/15 / #20150065565

Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Compounds of formula (a) and (b) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, sglt2 inhibitors).. . ... Pfizer Inc

03/05/15 / #20150065513

Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Compounds of formula (a) and (b) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, sglt2 inhibitors).. . ... Pfizer Inc

03/05/15 / #20150065512

Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Compounds of formula (a) and (b) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, sglt2 inhibitors).. . ... Pfizer Inc

02/05/15 / #the present invention relates to indole and indazole compounds of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

02/05/15 / #20150037328

Anti-cxcr4 antibodies and antibody-drug conjugates

The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (cxcr4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. ... Pfizer Inc

01/29/15 / #20150031735

Solid forms of a transthyretin dissociation inhibitor

The present invention relates to solid forms of the n-methyl-d-glucamine (meglumine) salt of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.. ... Pfizer Inc

01/29/15 / #20150031108

Processes for preparing peptide conjugates and linkers

The present invention provides a process for preparing a compound of formula 5b, as well as intermediates thereof, and novel classes of compounds useful in process for preparing these and similar compounds.. . ... Pfizer Inc

01/22/15 / #the invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

01/08/15 / #the invention provides a compound of formula (i)

Pfizer Inc.

. . ... Pfizer Inc

01/08/15 / #20150011514

Celecoxib compositions

Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.. ... Pfizer Inc

01/01/15 / #the present invention provides, in part, compounds of formula i:

Pfizer Inc.

. . ... Pfizer Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pfizer Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pfizer Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###